NCT00431015View on ClinicalTrials.gov

Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

August 31, 2011

Study Completion Date

December 31, 2011

Conditions
Lung Cancer
Interventions
DRUG

IPI-504

IV Hsp90 inhibitor

Trial Locations (11)

30912

Medical College of Georgia, Augusta

33140

Mount Sinai Comprehensive Cancer Center, Miami

33612

H. Lee Moffitt Cancer Center, Tampa

75201

Mary Crowley Cancer Research Centers - Medical City, Dallas

75246

Mary Crowley Cancer Research Centers - Baylor, Dallas

90048

Cedars-Sinai Medical Center, Los Angeles

98109

Seattle Cancer Care Alliance, Seattle

06519

Yale Comprehensive Cancer Center, New Haven

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

07601

Hackensack University Medical Center, Hackensack

Sponsors
All Listed Sponsors
lead

Infinity Pharmaceuticals, Inc.

INDUSTRY